Table 8.
Predicting Factors for CR of DEB-TACE Treatment in Patients With HCC.a
| Parameters | Univariate Logistic Regression | Multivariate Logistic Regression | ||||||
|---|---|---|---|---|---|---|---|---|
| P Value | OR | 95% CI | P Value | OR | 95% CI | |||
| Lower | Higher | Lower | Higher | |||||
| Age ≥ 60 years | .464 | 0.578 | 0.133 | 2.505 | - | - | - | - |
| Gender, Female | .924 | 0.917 | 0.153 | 5.508 | - | - | - | - |
| HBVb | .088 | 0.179 | 0.025 | 1.293 | - | - | - | - |
| Drink | .603 | 0.662 | 0.140 | 3.123 | - | - | - | - |
| Cirrhosis | .282 | 2.333 | 0.499 | 10.907 | - | - | - | - |
| Multifocal vs unifocal | .968 | 0.971 | 0.222 | 4.243 | - | - | - | - |
| Largest nodule size ≥5.7 cm | .208 | 0.371 | 0.079 | 1.738 | - | - | - | - |
| Bilobar vs unilobar | .586 | 1.571 | 0.309 | 7.989 | - | - | - | - |
| Portal vein invasion | .117 | 0.172 | 0.019 | 1.551 | - | - | - | - |
| Hepatic vein invasionc | - | - | - | - | - | - | - | - |
| Higher ECOG c | - | - | - | - | - | - | - | - |
| Higher Child-pugh stagec | - | - | - | - | - | - | - | - |
| Higher BCLC stage | .267 | 0.570 | 0.211 | 1.537 | - | - | - | - |
| WBC >4.80, ×109 cell/L | .846 | 1.154 | 0.272 | 4.895 | - | - | - | - |
| RBC >4.01, ×1012 cell/L | .726 | 1.300 | 0.300 | 5.637 | - | - | - | - |
| ANC%>64.10 | .208 | 0.371 | 0.079 | 1.738 | - | - | - | - |
| HB >12.70, g/L | .478 | 1.750 | 0.373 | 8.201 | - | - | - | - |
| PLT >97.00, ×109 cell/L | .130 | 3.167 | 0.711 | 14.096 | - | - | - | - |
| ALB >37.20, g/L | .150 | 3.111 | 0.663 | 14.596 | - | - | - | - |
| TP >66.70, g/L | .464 | 1.731 | 0.399 | 7.505 | - | - | - | - |
| TBIL >17.10, μmol/L | .264 | 0.431 | 0.099 | 1.886 | - | - | - | - |
| TBA >14.35, I/L | .355 | 0.500 | 0.115 | 2.175 | - | - | - | - |
| ALT >31.00, μ/L | .464 | 0.578 | 0.133 | 2.505 | - | - | - | - |
| AST >40.00, μ/L | .025 | 0.139 | 0.025 | 0.785 | .073 | 0.089 | 0.006 | 1.251 |
| ALP >147.00, μ/L | .264 | 2.318 | 0.530 | 10.133 | - | - | - | - |
| BCr >66.00, μmol/L | .208 | 2.692 | 0.575 | 12.596 | - | - | - | - |
| BUN >3.92, mmol/La | .037 | 10.385 | 1.156 | 93.293 | - | - | - | - |
| AFP >18.46, μg/L | .968 | 0.971 | 0.222 | 4.243 | - | - | - | - |
| CEA >2.74, μg/Lb | - | - | - | - | - | - | - | - |
| CA199 >24.80, kU/L | .038 | 0.162 | 0.029 | 0.908 | .041 | 0.066 | 0.005 | 0.891 |
| Previous cTACE | .654 | 1.407 | 0.316 | 6.265 | - | - | - | - |
| Previous Surgeryc | - | - | - | - | - | - | - | - |
| Previous systematic chemotherapy c | - | - | - | - | - | - | - | - |
| Previous radiofrequency ablation c | - | - | - | - | - | - | - | - |
| Previous targeted therapyc | - | - | - | - | - | - | - | - |
| Adriamycin drug (chemoembolization reagents)c | - | - | - | - | - | - | - | - |
| Irinotecan (Chemoembolization reagents) | .775 | 1.444 | 0.117 | 17.904 | - | - | - | - |
| Combination of ordinary embolization agent | .208 | 0.371 | 0.079 | 1.738 | - | - | - | - |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha fetoprotein; ALP, alkaline phosphatase; ALB, albumin; ANC, absolute neutrophil count; BUN, blood urea nitrogen; BCLC, Barcelona Clinic Liver Cancer; BCr, blood creatinine; CEA, carcino-embryonic antigen; CA199, carbohydrate antigen199; cTACE, conventional transarterial chemo-embolization; ECOG, Eastern Cooperative Oncology Group; HB, hemoglobin; HCC, hepatocellular carcinoma; HBV, hepatic b virus; PLT, platelet; RBC, red blood cell; TP, total protein; TBIL, total bilirubin; TBA, total bile acid; WBC, while blood cell.
aData were presented as P value, OR (odds ratio), and 95% CI. Significance was determined by univariate and multivariate logistic regression analysis. All factors with P value < .1 in univariate model were further analyzed by multivariate model. P value < .05 was considered significant.
bDue to the high relevance among “HBV,” “AST,” “BUN,” and “CA199,” and lack of CR events or non-CR events, “HBV” and “BUN” were not available for multivariate logistic regression.
cDue to the lack of CR events or non-CR events, “hepatic vein invasion,” “higher ECOG,” “higher child-pugh stage,” “CEA >2.74 (μg/L),” “previous surgery,” “previous systematic chemotherapy,” “previous radiofrequency ablation,” “previous targeted therapy,” and “adriamycin drug(chemoembolization reagents)” were not available for univariate logistic model. The boldface values stand for values with statistical significance.